Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
1.59 USD | -5.92% | -5.92% | -42.60% |
Mar. 18 | Transcript : Biofrontera Inc., Q4 2023 Earnings Call, Mar 18, 2024 | |
Mar. 15 | Biofrontera Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023 | CI |
Valuation
Fiscal Period: December | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
---|---|---|---|---|---|---|
Capitalization 1 | 128.6 | 24.47 | 4.204 | 8.092 | - | - |
Enterprise Value (EV) 1 | 128.6 | 24.47 | 4.204 | 8.092 | 8.092 | 8.092 |
P/E ratio | -1.76 x | -30.6 x | -0.21 x | -0.49 x | -2.92 x | 1.94 x |
Yield | - | - | - | - | - | - |
Capitalization / Revenue | 5.34 x | 0.85 x | 0.12 x | 0.2 x | 0.16 x | 0.12 x |
EV / Revenue | 5.34 x | 0.85 x | 0.12 x | 0.2 x | 0.16 x | 0.12 x |
EV / EBITDA | - | - | - | - | - | - |
EV / FCF | - | - | - | - | - | - |
FCF Yield | - | - | - | - | - | - |
Price to Book | - | - | - | - | - | - |
Nbr of stocks (in thousands) | 855 | 1,335 | 1,518 | 5,089 | - | - |
Reference price 2 | 150.4 | 18.33 | 2.770 | 1.590 | 1.590 | 1.590 |
Announcement Date | 4/8/22 | 3/8/23 | 3/15/24 | - | - | - |
Income Statement Evolution (Annual data)
Fiscal Period: December | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
---|---|---|---|---|---|---|---|
Net sales 1 | - | 24.1 | 28.67 | 34.07 | 40.7 | 49.94 | 65.29 |
EBITDA | - | - | - | - | - | - | - |
EBIT 1 | - | -25.2 | -18.58 | -22.68 | -13.25 | -3.13 | 7.766 |
Operating Margin | - | -104.57% | -64.8% | -66.56% | -32.55% | -6.27% | 11.89% |
Earnings before Tax (EBT) 1 | - | -37.66 | -0.608 | -20.12 | -16.02 | -3.08 | 7.866 |
Net income 1 | -10.99 | -37.71 | -0.64 | -20.13 | -16.02 | -3.08 | 6.686 |
Net margin | - | -156.49% | -2.23% | -59.09% | -39.37% | -6.17% | 10.24% |
EPS 2 | -9,590 | -85.60 | -0.6000 | -13.02 | -3.245 | -0.5450 | 0.8200 |
Free Cash Flow | - | - | - | - | - | - | - |
FCF margin | - | - | - | - | - | - | - |
FCF Conversion (EBITDA) | - | - | - | - | - | - | - |
FCF Conversion (Net income) | - | - | - | - | - | - | - |
Dividend per Share | - | - | - | - | - | - | - |
Announcement Date | 5/7/21 | 4/8/22 | 3/8/23 | 3/15/24 | - | - | - |
Income Statement Evolution (Quarterly data)
Fiscal Period: December | 2021 Q3 | 2021 Q4 | 2022 Q1 | 2022 Q2 | 2022 Q3 | 2022 Q4 | 2023 Q1 | 2023 Q2 | 2023 Q3 | 2023 Q4 | 2024 Q1 | 2024 Q2 | 2024 Q3 | 2024 Q4 | 2025 Q1 |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Net sales 1 | 4.334 | 9.168 | 9.751 | 4.457 | 4.322 | 10.14 | 8.733 | 5.848 | 8.896 | 10.6 | 10.86 | 8.606 | 7.956 | 13.28 | 12.5 |
EBITDA | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
EBIT 1 | - | -1.88 | -3.11 | -6.212 | -3.639 | -5.62 | -5.492 | -8.699 | -4.62 | -3.865 | -3.341 | -4.422 | -5.562 | 0.0765 | -1 |
Operating Margin | - | -20.51% | -31.89% | -139.38% | -84.2% | -55.4% | -62.89% | -148.75% | -51.93% | -36.48% | -30.77% | -51.38% | -69.9% | 0.58% | -8% |
Earnings before Tax (EBT) 1 | - | -14.5 | 5.591 | -0.85 | -2.565 | -2.784 | -7.473 | -9.823 | -6.341 | 3.52 | -4.703 | -5.784 | -5.586 | 0.0515 | -1 |
Net income 1 | - | -14.5 | 5.561 | -0.85 | -2.566 | -2.785 | -7.478 | -9.837 | -6.342 | 3.526 | -4.703 | -5.784 | -5.586 | 0.0515 | -1 |
Net margin | - | -158.21% | 57.03% | -19.07% | -59.37% | -27.45% | -85.63% | -168.21% | -71.29% | 33.28% | -43.32% | -67.21% | -70.21% | 0.39% | -8% |
EPS 2 | - | -25.80 | 6.400 | -1.000 | -2.200 | -2.800 | -5.600 | -7.230 | -4.640 | 4.550 | -1.170 | -1.125 | -1.075 | 0.005000 | -0.1900 |
Dividend per Share | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Announcement Date | 11/30/21 | 4/8/22 | 5/13/22 | 8/12/22 | 11/14/22 | 3/8/23 | 5/12/23 | 8/11/23 | 11/9/23 | 3/15/24 | - | - | - | - | - |
Balance Sheet Analysis
Fiscal Period: December | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
---|---|---|---|---|---|---|---|
Net Debt | - | - | - | - | - | - | - |
Net Cash position | - | - | - | - | - | - | - |
Leverage (Debt/EBITDA) | - | - | - | - | - | - | - |
Free Cash Flow | - | - | - | - | - | - | - |
ROE (net income / shareholders' equity) | - | - | - | - | - | - | - |
ROA (Net income/ Total Assets) | - | - | - | - | - | - | - |
Assets 1 | - | - | - | - | - | - | - |
Book Value Per Share | - | - | - | - | - | - | - |
Cash Flow per Share | - | - | - | - | - | - | - |
Capex 1 | - | 0.01 | 0.04 | - | 0.7 | 0.8 | - |
Capex / Sales | - | 0.05% | 0.13% | - | 1.72% | 1.6% | - |
Announcement Date | 5/7/21 | 4/8/22 | 3/8/23 | 3/15/24 | - | - | - |
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-42.60% | 8.09M | |
+25.83% | 661B | |
+27.00% | 566B | |
-6.76% | 352B | |
+20.34% | 332B | |
+3.00% | 283B | |
+13.09% | 231B | |
+5.46% | 200B | |
-9.61% | 195B | |
-6.26% | 145B |
- Stock Market
- Equities
- BFRI Stock
- Financials Biofrontera Inc.